developing diagnostics for emerging and neglected infectious diseases

Latest News

About Us

Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology.  We collaborate with a global community of researchers to develop and translate new technologies into accessible products for clinical diagnostics and research applications.  Kephera has recently been funded for development of new tests for several infectious diseases of global significance.


Our mission is to promote more effective and more affordable medical treatment through faster, point-of-care diagnosis. 

Kephera’s goal is to accelerate the development of rapid, point-of-care tests for emerging infectious diseases to provide the critical diagnostic tools for medical and public health response in real-time, when and where they are most urgently needed.  We combine innovative technologies in molecular biology, immunology, chemistry and device engineering to develop novel diagnostics for this purpose.


Emerging infectious diseases are responsible for over one billion cases of illness every year and continue to be the leading cause of death worldwide.  Vector-borne diseases in particular, including malaria, dengue, Chagas, leishmania and others are major public health problems with over half of the world’s population at risk according to the World Health Organization.  Collectively, these diseases account for an annual global economic burden in the hundreds of billions of dollars. Fast and accurate diagnosis is the key to effective treatment for infectious diseases and to epidemiological monitoring on which intervention programs depend.  Diagnosis has traditionally relied on sophisticated laboratory tests, however, which are costly, complex, slow to develop, and not widely available. The unpredictability and speed with which many new infectious diseases emerge and spread makes the traditional approach unworkable – a recent example being the invasion of Zika virus in the western hemisphere in 2015.  Consequently, there is a critical need for the rapid development of diagnostics in accessible point-of-care formats that can timely and effectively address the global threat of emerging infectious diseases.


Andrew E. Levin, PhD

Founder, Chief Executive Officer and Scientific Director

Kephera Diagnostics was founded by Dr. Levin in 2016. He has spent over 20 years in the development and commercialization of diagnostic test products for emerging infectious diseases including HIV, HTLV, Lyme disease, Cysticercosis, Hydatid Disease, Babesiosis, Ehrlichiosis, SARS, Anthrax and others, and brought five assays through clinical trials to FDA clearance as in vitro diagnostics.  Dr. Levin received his A.B. in Biochemistry from Princeton University and Ph.D. in Molecular Biology from the University of Wisconsin. He carried out research at the Centre de Génétique Moléculaire in Gif-sur-Yvette, France under a NATO grant, and completed postdoctoral training at Harvard University prior to founding his first company.


Kephera Diagnostics is a team of passionate scientists, working to brighten the future of diagnostics for emerging and neglected infectious diseases. Kephera seeks talented and enthusiastic team players inspired to make an impact on global public health by delivering better diagnostic information to patients at the point of care. Kephera offers a dynamic start-up environment combining flexibility, challenging work and the opportunity to participate in a new venture. Kephera is committed to a diverse workplace.

Open Positions

Research Assistant (Closed)

Read More

Responsibilities will include laboratory work in assay development and associated documentation under direction of a staff scientist.

Qualified candidates should be entrepreneurial in spirit and ready for multiple scientific and business challenges, have a BS degree in a life science and have experience with laboratory techniques such as electrophoresis, immunoassays and immunochemistry, chromatography, and cell culture. Familiarity with typical MS Office software and ability to communicate clearly in writing and in presentations is essential. The successful candidate will contribute significantly to the research program and be involved in multiple aspects of the projects from basic research to clinical studies.

Scientist - Assay Development (Closed)

Read More

Responsibilities will include development and validation of immunoassays in rapid formats, ELISA and Western Blot, documentation for product transfer, and participation in clinical studies for regulatory submission.

The successful candidate will possess a Ph.D. in biochemistry, molecular biology or other life science field and be well versed in biochemistry, molecular biology, microbiology and infectious diseases. Your credentials should include assay development experience in the field of in vitro diagnostics, especially for infectious diseases. At least 1 year work experience post-PhD, preferably including industry experience in a cGMP environment, is required. Familiarity with immunoassays, rapid assays, conjugation techniques, protein purification and characterization, mammalian cell culture, pathogen biochemistry and microbiological methods is desirable. Strong laboratory and organizational skills, capability for independent problem-solving as well as teamwork, and excellent communication skills are essential. Product development experience would be a plus.


At Kephera, we are developing rapid tests for infectious diseases using novel immunochemistry in point-of-care format. Our proprietary assay technology is based on principles of particle interaction combined with a simple device, which together enable rapid detection of specific antibodies or antigens associated with the target pathogen. The broadly enabling technology is applicable to a wide range of disease targets and applications. Kephera’s expertise extends from antigen discovery using microarrays and peptide libraries to assay development, clinical studies and validation. We work with some of the leading academic research institutions in the U.S. and internationally, along with researchers at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).

Product Pipeline

Diagnostic Test for Zika Virus Infection

Kephera is developing a test for Zika virus infection with support from a grant from the National Institutes of Health. Kephera’s Zika project is based on the identification of Zika-specific and Dengue-specific epitopes within the viral genome, from which an immunoassay will be developed in convenient and cost-effective ELISA format, and ultimately translated to point-of-care format.  To this end, we are working in collaboration with medical research institutes in the U.S. and Latin America to analyze the immunological reactivities of patient sera from Zika and Dengue-endemic regions, using a variety of epitope mapping techniques. Epitopes selected based on ability to differentiate viral infections will then be expressed synthetically or as recombinant antigens for assay development.

What is Zika?

Zika emerged in 2015 as a major public health threat in the western hemisphere, leading to an urgent need for diagnostic tools for clinical and epidemiological use. Although primary Zika infection is typically accompanied by mild symptoms, the virus has been linked to severe birth defects in infants born to infected mothers, and to potentially fatal neurological conditions including Guillain Barré syndrome.

How Does it Spread?

Zika is transmitted by the same Aedes mosquito species that transmit the related Dengue and Yellow Fever viruses, along with a variety of others such as Chikungunya.  As Dengue virus is endemic in much of the tropical world, background immunological reactivity to Dengue tends to confound the serological diagnosis of Zika infection.  Accurate diagnosis of Zika infection in the post-viremic or convalescent phase continues to be a significant challenge, calling for the development of tests which are truly specific for this virus.

How is it Diagnosed?

Zika infection can be detected by molecular assays, but this approach is only useful during the relatively brief viremic phase, typically several weeks or less. After this period, individuals including pregnant women at risk for complications caused by prior infection can only be identified by serologic assays. The close genetic relationship between Zika and other flaviviruses has made serological diagnosis extremely difficult, however, due to cross-reactivities between viral antigens.

Chagas Disease - Rapid Test

With support from a National Institutes of Health grant, Kephera is developing a new point-of-care test for Chagas disease.  Kephera scientists have identified and are purifying parasite components which promise to yield a highly sensitive and specific test.  Together with our academic collaborators in the U.S. and Latin America, we are evaluating the performance of the test as it is developed in our laboratory.

What is Chagas?

Chagas disease, a chronic infection with the parasite Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, outranking even malaria. Because the disease can be asymptomatic for a long period of time, often years, most cases are not detected until the chronic stage. In the interim, infected individuals remain – most unknowingly – T. cruzi carriers.  Infection can cause severe gastrointestinal and cardiac disease, and cardiomyopathy leading to early death is a major cause of lost productivity. The global economic burden of Chagas disease is estimated at $7-19 billion/year.  Consequently, the World Health Organization (WHO) has identified Chagas disease as a top priority for public health intervention.

How Does it Spread?

Chagas disease is endemic to large regions of Latin America, where it is transmitted to humans by the triatomid bug.  Transmission can also occur through blood transfusion, organ transplant and congenitally. More than 70 million people live at risk, resulting in over 10 million infections.

How is it Currently Diagnosed?

Chagas disease can be diagnosed through the detection of antibodies to the parasite in a patient’s blood.  A variety of antibody tests have been developed, with varying performance. Because the sensitivity as well as the specificity of serologic tests can be compromised by cross-reactive antigens and by genetic diversity among T. cruzi strains, the current diagnostic approach relies on comparing and combining the results of multiple independent tests.  The shortcomings of the current generation of tests in sensitivity or specificity point to the need for newer, more accurate tests, which can preferably be carried out outside a laboratory.


NIAID awards new grant to Kephera Diagnostics for Zika virus test

National Institute of Allergy and Infectious Diseases awards grant to Kephera Diagnostics for Zika virus test Framingham, MA – August 18, 2017.  Kephera diagnostics announced today that it has been awarded a two-year, $598,136 SBIR grant by the National Institute of Allergy and Infectious Diseases, an agency of the National Institutes of Health (NIH), to…

Read more

Contact Us



Kephera Diagnostics, LLC

1 Grant Street, Suite 300

Framingham, MA 01702